Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
Pancreatic islet transplantation has shown short-term efficacy with some evidence of long-term efficacy, as well as a satisfactory safety profile, according to the Guidance issued by NICE (National Institute for Health and Clinical Excellence), the UK medicines regulator. The National Specialised Commissioning Team (NSCT) formerly National Commissioning Group (NCG) has approved reimbursement for this procedure as a treatment option for type 1 diabetes patients experiencing hypoglycemic episodes that occur without warning and cannot be managed with current treatments. Type 1 diabetes is a disease affecting some 20 million people worldwide. In Europe only the strict UK regulator and Swiss health authorities have approved NHS reimbursement for this procedure that in the future may get even more space as a treatment option in patients with type 1 diabetes thanks to Reparixin. Developed by Domp?, one of Italy?s leading biopharmaceutical companies, Reparixin has shown to improve transplantation efficiency.
?Over the last 15 years, transplantation of pancreatic islet cells from donors into patients with severe type 1 diabetes, has moved from a relatively rare experimental procedure, to a more commonplace successful clinical treatment? - said Paul Johnson, Director of the Oxford Islet Transplant Programme.
http://www.pharmiweb.com/pressreleases/pressrel.asp?ROW_ID=69880#.UQaNb7_sySo
?Over the last 15 years, transplantation of pancreatic islet cells from donors into patients with severe type 1 diabetes, has moved from a relatively rare experimental procedure, to a more commonplace successful clinical treatment? - said Paul Johnson, Director of the Oxford Islet Transplant Programme.
http://www.pharmiweb.com/pressreleases/pressrel.asp?ROW_ID=69880#.UQaNb7_sySo